Ensol Biosciences엔솔바이오사이언스
140610 · KONEX · ₩140610 · 엔솔바이오사이언스
- Market cap
- ₩128B
- Enterprise value
- —
- P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- ROE
- —
- Net margin
- —
Financial statements not available yet. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−50.2% from the high
₩7,750Today: ₩8,200 – ₩9,400₩17,900
Returns
- 1W−2.7%
- 1M−11.7%
- 3M−13.5%
- 6M−35.3%
- YTD−32.1%
- 1Y−42.4%
- Volume today
- 3,118
- 0.5× the 20-day average
- Traded today
- ₩27M
- Listed shares
- 14,376,402
- EPS (12 months)
- —
🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Why is it moving?
+7.2% on Oct 28, 2026.
We found no news, filing or broker report explaining it yet. Moves without news happen; it may come later.
Possible reasons, not certainties. Not financial advice.
Signals
Quiet- BuzzQuietBuzz 34 of 100 (50 is a normal day for this stock).
- MomentumWeak-11.9% over the last month; the price is below its 20-day average.
- News impactLow1 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Ensol Biosciences stock overview
Ensol Biosciences (엔솔바이오사이언스, KRX: 140610) is listed on KONEX, in the Biotech & Pharma sector. The company specializes in short peptide research and development that regulates protein-protein interactions (PPI), with a focus on treatments for diseases that currently lack therapeutic alternatives. Its shares closed at ₩8,920 on Oct 28, 2026, up 7.21% on the day, giving it a market value of ₩128B.
Key facts
- Market cap
- ₩128B
- Sector
- Biotech & Pharma
- Latest price change
- +7.21%
- As of
- Oct 28, 2026
- Main business
- The company specializes in short peptide research and development that regulates protein-protein interactions (PPI), with a focus on treatments for diseases that currently lack therapeutic alternatives.
Quick answers about Ensol Biosciences
- What does Ensol Biosciences do?
- The company specializes in short peptide research and development that regulates protein-protein interactions (PPI), with a focus on treatments for diseases that currently lack therapeutic alternatives. Its core clinical programs include P2K for degenerative disc disease, P2K for expanded indications, E1K for knee osteoarthritis, and C1K as an anticancer combination therapy, alongside follow-on programs in Alzheimer's disease, obesity, and PDC cancer treatment. Its revenue comes mainly from licensing technology and from JointVex, a veterinary osteoarthritis drug sold in Korea, and its operations are based in Daejeon, with a drug discovery center in Daegu-Gyeongbuk.
- What is the market cap of Ensol Biosciences?
- The market capitalisation of Ensol Biosciences was ₩128B at the close on Oct 28, 2026.
- Who are the largest shareholders of Ensol Biosciences?
- According to the latest official filings, the largest reported holders are Hyeong In-woo (34.37%, as of Jul 13, 2026); Kim Hae-jin (17.72%, as of Jan 8, 2025); Magnine Investment (5.30%, as of May 27, 2026).
- When is the next earnings report from Ensol Biosciences?
- Korean companies rarely announce results dates in advance. Based on when Ensol Biosciences filed the same report in past years, its next annual results is expected between Mar 18, 2027 and Mar 29, 2027.
Company profile
The company specializes in short peptide research and development that regulates protein-protein interactions (PPI), with a focus on treatments for diseases that currently lack therapeutic alternatives. Its core clinical programs include P2K for degenerative disc disease, P2K for expanded indications, E1K for knee osteoarthritis, and C1K as an anticancer combination therapy, alongside follow-on programs in Alzheimer's disease, obesity, and PDC cancer treatment. Its revenue comes mainly from licensing technology and from JointVex, a veterinary osteoarthritis drug sold in Korea, and its operations are based in Daejeon, with a drug discovery center in Daegu-Gyeongbuk.
Written by AI from the company's latest annual report.
- Korean name
- 엔솔바이오사이언스
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 김해진
- Founded
- Feb 2001
- Listed
- Sep 2018
- Listed shares
- 14,376,402
- Fiscal year ends
- Month 12
- Website
- www.ensolbio.co.kr
Similar companies
- Samsung Biologics207940 · ₩64T₩1,372,000−0.15%
- Celltrion068270 · ₩44T₩189,800+0.64%
- Alteogen196170 · ₩16T₩223,000+2.06%
- SK biopharmaceuticals326030 · ₩5.9T₩75,200+0.40%
- Yuhan000100 · ₩5.7T₩77,300−3.38%
- HLB028300 · ₩5.4T₩40,650+1.88%
- Hanmi Pharm128940 · ₩4.7T₩369,500+5.42%
- SAM Chun Dang Pharm000250 · ₩4.5T₩190,000+1.28%
Recent filings
See all- Investor relations (IR) eventOct 21, 2026
- 5%+ holding reportJul 13, 2026
- Investor relations (IR) eventJul 3, 2026
- Change in Designated Adviser Appointment AgreementJun 30, 2026
- Securities Issuance Results (Voluntary Disclosure) (Third-Party Allotment Rights Offering)Jun 19, 2026
Titles in Korean until English translations are added.
Also known as: Ensol Biosciences / 엔솔바이오사이언스 / 140610 / KRX:140610
Source: KRX statistical information